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Introduction
Vaccination is an effective tool against several infectious
agents including influenza. In 2010, the Advisory Com-
mittee on Immunization Practices (ACIP) recommended
influenza A H1N1/2009 immunization for high risk
groups, including juvenile idiopathic arthritis (JIA)
patients and more recently the EULAR task force rein-
forced the importance of vaccination in immunosup-
pressed pediatric rheumatologic patients. We have
recently shown that Influenza A H1N1/2009 vaccination
generated protective antibody production with short-term
safety profile among 93 JIA patients, but the possible
impact of the vaccine in autoimmune response in JIA
have not been studied. Therefore, we aimed to assess the
production of some autoantibodies generated following
influenza H1N1 vaccination in JIA patients.
Objectives
To assess the autoimmune response and H1N1 serology
following influenza H1N1 vaccination in patients with JIA.
Methods
Cepa A/California/7/2009 (NYMC X-179A) anti-H1N1
was used to vaccinate JIA patients: 1 dose of immunization
was given to all participants and those <9yrs of age
received a second booster 3 weeks apart. Sera were ana-
lyzed before and 3 weeks following complete vaccination.
Serology against H1N1 virus was performed by hemagglu-
tination inhibition antibody assay, rheumatoid factor (RF)
by latex fixation test, antinuclear antibodies (ANA) by IIF,
IgM and IgG anticardiolipin (aCL) by ELISA.
Results
Among 98 JIA patients that were vaccinated, 58 sera
were available for this study. Mean age of 58 JIA patients
was 23.9 ± 9.5 yrs, 38 were females and 20 males with
mean disease duration of 14.7 ± 10.1 yrs. JIA subtypes
were: 33 (57%) poliarticular, 10 (17%) oligoarticular,
6 (10%) systemic and 9 (16%) other. Sixteen patients
were off drugs while 42 (72%) were under different phar-
macotherapy: 32 (55%) were on 1 DMARD/IS, 10 (17%)
on 2 DMARDs/IS, 19 (33%) antimalarials, 29 (50%)
MTX, 8(14%) sulfasalazine, 6 (10%) anti-TNFs, 4 (7%)
abatacept; no patient was using prednisone >0.5 mg/kg/d.
Seroprotection rates against H1N1 influenza increased
from 23 to 83% and seroconversion rates were achieved
in 78% JIA. Prior to vaccination, 31(53.4%) JIA patients
were ANA+, 6(10.3%) RF+, and 4 (7%) IgM + IgG aCL+.
After complete H1N1 vaccination, positivity for ANA
remained the same whereas 1 patient became negative
for IgG aCL, and another for RF, IgM and IgG aCL. One
(1.7%) patient turned low titer IgG aCL+.
Conclusion
Vaccination of JIA patients against pandemic influenza
A (H1N1) generated successful protective antibody
production without the induction of autoantibody
production, except for 1 patient that became positive
for low titer IgG aCL, supporting its safety.
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